The Joint Action Personalised Cancer Medicine (JAPCM) will make diverse types of cancer data accessible: genomics, imaging, medical, clinical, environmental and socio-economic. It will use and enhance federated and interoperable systems for securely identifying, sharing, processing and reusing FAIR data across borders and offer them via community-driven analysis environments.
JAPCM well curated data sets will be essential input for reproducible and robust analytics and computational methods – including machine learning and artificial intelligence. JAPCM five use cases will cover the patient journey from cancer prevention over diagnosis to treatment, laying the foundation of data trajectories and workflows for future EU projects.
JA PCM ARMS
Prevention
Medicine
Follow-up
Highlights
Subscribe to receive the latest updates and news on personalised medicine initiatives in Europe